Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Seeking Alpha
TVTX's market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating primary IgAN. Recent FDA REMS modifications for FILSPARI have eased monitoring requirements, improving its commercial prospects and patient accessibility. Potential label expansion into FSGS should further accelerate revenue growth and support continued market cap appreciation. We Are/DigitalVision via Getty Images This is my third Travere Therapeutics ( TVTX ) article. In my previous article , I rated Travere as a 'Buy.' It has since rocketed upwards ~107%. Powered by FILSPARI's existing and anticipated approvals, Travere is on a tear This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of TVTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relation
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.MarketBeat
- Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]Yahoo! Finance
- Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TVTX's page on the SEC website